Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make ...

The Michigan Supreme Court heard oral arguments concerning a blocked investigation into alleged price gouging practices from ...

NEW YORK (Reuters) -U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which ...

Eli Lilly (NYSE:LLY) has expanded its ongoing collaboration with Swiss biotech KeyBioscience in a bid to obtain global rights ...

KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Drug giant Eli Lilly announced Thomas Fuchs as its first chief AI officer. Previously, Fuchs was director of the Hasso ...